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ABSTRACT
Lamivudine has demonstrated efficacy in the treatment and prevention of hepatitis B virus (HBV) reactivation
after hematopoietic stem cell transplantation (HSCT). However, most of these studies involved short durations
of prophylaxis, so there is significant concern regarding lamivudine resistance in these patients. Between
March 1984 and November 2002, 71 HBV surface antigen–positive HSCT recipients, including a subgroup of
16 who received pretransplantation lamivudine therapy, which was continued into the posttransplantation
period to prevent reactivation hepatitis, were enrolled onto our study. The efficacy of lamivudine therapy was
first evaluated for the subgroup of 16 patients in terms of treatment response, lamivudine resistance, and viral
recurrence after discontinuation by using virologic assays. Efficacy was then evaluated for all patients in terms
of the hazards of lamivudine therapy for reactivation hepatitis after transplantation. During a median lamivu-
dine therapy period of 73 weeks (range, 19-153 weeks), the initial response showed a median reduction of 2.54
log10 in serum HBV DNA (0.28 to 6.72 range). Lamivudine-resistant mutations were detected in 10 (63%)
of 16 patients during therapy, and 1 (12%) of 16 patients finally developed a viral breakthrough. At a median
follow-up of 30 months after discontinuation, 3 (27%) of 11 cases had recurrence of HBV infection. Despite
the emergence of the mutations, no deaths were due to HBV reactivation or severe cases of hepatitis. In the
Cox proportion regression model regarding reactivation hepatitis after transplantation of all enrolled patients,
lamivudine therapy was found to be the only favorable factor for the event, with a hazard ratio of 0.122 (95%
confidence interval, 0.016-0.908; P .040). In conclusion, extended lamivudine therapy is safe and effective for
the prevention of HBV reactivation in an HSCT setting and significantly decreases reactivation hepatitis after
transplantation.
© 2006 American Society for Blood and Marrow Transplantation
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oNTRODUCTION
The pyrimidine nucleoside analogue lamivudine, a
egative enantiomer of 3-thiacytidine, has success-
ully rescued life-threatening hepatitis B virus
HBV) reactivations in several reported cases after
ntensive chemotherapy [1-3] and hematopoietic
tem cell transplantation (HSCT) [4-7]. Further-
ore, lamivudine is well tolerated and can be used to t
4revent subsequent reactivations, thus allowing com-
letion of chemotherapy and subsequent HSCT
6-17]. Therefore, lamivudine can be administered
efore transplantation to hepatitis B surface antigen
HBsAg)–positive HSCT recipients who have demon-
trated reactivation of HBV during previous courses
f chemotherapy. Lamivudine therapy can be ex-
ended into the posttransplantation period, particu-
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Extended Lamivudine Therapy in HSCT Recipients
Barly to cover periods of increased immunosuppression
hat may be required to treat exacerbations of graft-
ersus-host disease (GVHD) or if salvage therapy is
sed to treat relapse [6-11]. However, most of these
tudies described short durations of prophylaxis, and
here is signiﬁcant concern regarding the potential of
amivudine resistance in such patients.
HBV infection is endemic in Taiwan: up to 14%
f its HSCT recipients are HBsAg positive [18]. In-
eed, posttransplantation HBV reactivation results in
igniﬁcant complications and deaths in these HSCT
ecipients [19-22]. Lamivudine became available at
ur institution in 1999 and was administered to
SCT recipients during the peritransplantation pe-
iod. In this study, the efﬁcacy of lamivudine therapy
as initially evaluated, in terms of treatment response,
amivudine resistance, and viral recurrence after dis-
ontinuation, by the use of virologic assays for a sub-
roup of 16 HBsAg-positive HSCT recipients who
eceived lamivudine therapy after transplantation to
revent HBV reactivation. Efﬁcacy was subsequently
valuated for all HBsAg-positive recipients in terms of
he hazards of lamivudine therapy for reactivation
epatitis after transplantation.
ATIENTS AND METHODS
tudy Population
Between March 1984 and November 2002, 85
16%) of 532 HBsAg-positive patients underwent
SCT in our institution [20-22]. With the exception
f 7 with hepatitis C virus coinfection and another 7
ith a follow-up of 2 months after transplantation,
ll remaining 71 recipients were enrolled onto the
tudy, including a subgroup of 16 patients who re-
eived lamivudine to prevent HBV reactivation hepa-
itis after transplantation since 1999. The efﬁcacy of
amivudine therapy was evaluated for the subgroup
ith lamivudine by using different virologic assays in
erms of treatment response, lamivudine resistance,
nd viral recurrence after discontinuation. The effect
f lamivudine therapy and other factors on HBV re-
ctivation hepatitis after transplantation was analyzed
or all 71 HBsAg-positive patients by using a Cox
roportion regression model. The study was approved
y the institutional review board of our institution.
ollow-up of patients continued until February 2005.
SCT Method and Lamivudine Therapy
In our institution, preparative regimens including
otal body irradiation (TBI) were administered to recip-
ents with severe aplastic anemia and acute lymphoid
eukemia, and those without TBI were administered to
atients with myeloid leukemia and lymphoma. In vitro
urging was not performed. The regimen for acute
VHD prophylaxis included a short course of meth- A
B&MTtrexate and cyclosporin A. The dose of cyclosporin A
as decreased by 5% weekly until 6 months after
ransplantation. Reduced-intensity ﬂudarabine-based
egimens were administered to allogeneic recipients
ged 45 years in 2000, in whom only cyclosporin A
as used as prophylaxis of acute GVHD. With the
xception of patients who received HSCT in the early
980s, all recipients received granulocyte colony-
timulating factor to support engraftment. For cyto-
egalovirus (CMV) infection, preemptive therapy
ather than primary prophylaxis was administered at
he onset of clinical symptoms accompanied by posi-
ive anti-CMV immunoglobulin (Ig)M, qualitative
olymerase chain reaction (PCR), or both. All recip-
ents and donors were followed up with liver function
ests and serologic tests (for hepatitis and CMV).
amivudine Therapy
Before the administration of lamivudine therapy,
ecipients and donors did not receive antiviral therapy
gainst HBV, intravenous immunoglobulin, or HBV
accinations within 12 weeks of the transplantation.
ince 1999, lamivudine therapy (100 mg/d orally)
as commenced in our HBsAg-positive HSCT re-
ipients before transplantation, including those
ith no previous events of HBV reactivation hepa-
itis before transplantation (ie, primary prophylaxis)
r those had already received lamivudine during con-
entional chemotherapy because of HBV reactivation
epatitis (ie, secondary prophylaxis). Therapy was ex-
ended into the posttransplantation period to prevent
BV reactivation. Discontinuation of lamivudine
herapy after transplantation was considered when re-
ipients satisﬁed all of the following criteria: (1) nor-
al biochemical liver function tests, (2) remitted un-
erlying disease with a low risk of relapse, and (3) no
se of immunosuppressive medications or their use at
aintenance dosages for 3 months. Sera collected
efore, during, and after therapy were stored at
20°C for use in virologic assays. Between March
000 and November 2002, 16 patients underwent
SCT and received lamivudine as described previ-
usly. During the same period, 2 of 5 HBsAg-positive
ecipients who were not given lamivudine therapy
ccording to the described schedule received it as
escue medication until the time of reactivation hep-
titis after transplantation.
ssays
Biochemical liver function tests and serology tests of
iral hepatitis. Liver function tests, including alanine
minotransferase (ALT), aspartate aminotransferase,
lkaline phosphate, -glutamyl transferase, and total
ilirubin (TB), and serology tests of hepatitis viruses
, B, C, and D were performed as previously de-
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8cribed [19-22]. The values of normal ranges were
40 IU/L for ALT and 1.6 mg/dL for TB.
HBV DNA assays. Viral DNA was extracted from
00 L of serum by using the High Pure Viral Nu-
leic Acid Kit (Roche Molecular Biochemicals, India-
apolis, IN) according to the manufacturer’s recom-
endations. DNA was dissolved in 50 L of elution
uffer for subsequent tests.
The serum HBV DNA value was semiquantita-
ively measured by dot-blot hybridization by using a
hosphorus 32–labeled HBV DNA probe (Bethesda
esearch Laboratories, Bethesda, MD) before 2000
21] and then quantitatively by real-time PCR assay
fter 2000. Real-time PCR was performed by the
ightCycler instrument (Roche Molecular Biochemi-
als, Mannheim, Germany), with the procedures
lightly modiﬁed from those previously described [23].
CR primers used in the ampliﬁcation reaction were
s follows: sense, 5=-GATGTGTCTGCGGCGTTT-
A-3=, and anti-sense, 5=-CTGAGGCCCACTCCCA-
A-3=. The detection limit was 102 copies per millili-
er. Because of its high sensitivity, only variations of
ore than 3-fold serum HBV DNA levels were consid-
red to reﬂect signiﬁcant changes, as recommended [24].
BV Genotypes, Variants, and Mutations
The genotype was examined for the sera at base-
ine and was performed by PCR ampliﬁcation with
enotype-speciﬁc primers, thus allowing genotype-
peciﬁc DNA bands on the gel electrophoresis iden-
iﬁed [25].
Variants and mutations were examined by using
era stored at the serial follow-up; the nomenclature
as based on workshop recommendations [26]. Vari-
nts of the basal core promoter (A1762T/G1764A) and
recore (G1896A) sites were determined by direct se-
uencing for PCR-ampliﬁed HBV DNA fragments
overing these sites, as previously described [22,27].
etection of speciﬁc mutations in the tyrosine-methi-
nine-aspartate-aspartate (YMDD) motif of HBV
olymerase, including substitutions of methionine by
aline or isoleucine (YVDD/YIDD, M550V/I for ge-
otype B and C) [28], was done by the ampliﬁcation-
reated restriction site analysis, as previously de-
cribed [29]. The presence of YMDD mutations was
onﬁrmed by gel electrophoresis and direct sequenc-
ng. This method detects the mutations when present
n only 1% of the viral populations [29]. Sequencing
f PCR-ampliﬁed products was performed as previ-
usly described [22].
efinitions
HBV reactivation hepatitis after transplantation.
epatitis was deﬁned as a serum ALT level 100
U/mL on 2 consecutive determinations at least 5 days
part. Hepatitis severity was classiﬁed as icteric when u
6linical jaundice with the serum TB level 1.6 mg/dL
as noted and was designated as fulminant when he-
atic encephalopathy and irregular blood coagulation
prothrombin time prolonged for 10 seconds) were
oted. With respect to the duration, the hepatitis was
esignated as acute (transient) if it lasted 6 months
r as chronic (persistent) if it lasted 6 months
17,21]. After other causes of posttransplantation hep-
titis were excluded, including CMV infection, veno-
cclusive disease, and acute and chronic GVHD, as
reviously described [30-32], HBV reactivation hepa-
itis was identiﬁed whenever there was laboratory evi-
ence of viral reactivation. Because the assays used were
ot universal for all our recipients, virologic evidence of
BV reactivation in HBsAg-positive HSCT recipients
ncluded (1) the appearance of serum hepatitis B early
ntigen (HBeAg; from negative to positive), HBV DNA
by dot-blot hybridization), and/or anti-hepatitis B
ore IgM [21] and/or (2) a quantitative increase of
erum HBV DNA to more than 10-fold that of the
re-exacerbation baseline [17]. Liver biopsy was per-
ormed, if possible, when the cause was not clear and
he recipient had a low risk of bleeding or infection.
Efﬁcacy of lamivudine therapy. Efﬁcacy was evalu-
ted in terms of treatment response, viral break-
hrough, and recurrence. Treatment response was ini-
ially assessed by using liver function tests, viral load
ssays, and speciﬁc antibody production [26]. A bio-
hemical response was indicated by normal serum
LT levels, and a virologic response was indicated by
he decline or maintenance of serum quantitative
BV-DNA levels and/or accompanying seroconver-
ion of HBsAg, HBeAg, or both. Furthermore, ac-
ording to the time course relative to lamivudine ther-
py, the response was further designated as initial
occurring within the ﬁrst 6 months), maintained (at
he time of last evaluation during extended therapy),
nd of treatment (at the time of discontinuing ther-
py), or sustained (6-12 months after discontinuing
herapy) [26]. Along with a maintained or end-of-
reatment response during lamivudine therapy, viral
reakthrough was identiﬁed if there was a reappear-
nce of serum HBV DNA of either a level103 copies
er milliliter (for recipients who had an undetectable
erum HBV DNA [ie, 102 copies per milliliter] at
he initial virologic response) or a 100-fold increase
bove the value at the initial virologic response (for
ecipients who did not have an undetectable serum
BV DNA level).
tatistical Analysis
Chi-squared or Fisher exact tests were used to
ompare the difference in events between different
roups. Cox proportional hazards regression analyses
sing a forward stepwise selection procedure were
sed to estimate hazards (with 95% conﬁdence inter-
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Extended Lamivudine Therapy in HSCT Recipients
Bals) for HBV reactivation hepatitis after transplanta-
ion, with adjustment for several independent factors,
ncluding the recipient’s sex, age, diagnosis (lym-
homa versus nonlymphoma), presence of HBeAg,
iver function tests just before HSCT, source of graft
autologous versus allogeneic), preparative regimen
TBI versus non-TBI), donor’s HBsAg status, and use
f lamivudine therapy. Most of these factors were
elected mainly according to ﬁndings from previous
eports [21] and data availability at the time of analy-
is. Kaplan-Meier curves were used to estimate the
umulative hazards of HBV reactivation hepatitis after
ransplantation. P values .05 were considered statis-
ically signiﬁcant. Statistical analyses were performed
ith SPSS version 10.0 (SPSS Inc., Chicago, IL).
ESULTS
aseline Characteristics of HSCT Recipients
eceiving Lamivudine Therapy
The baseline characteristics of the 16 patients who
eceived lamivudine therapy during the peritransplan-
ation period are summarized in Table 1. Patient 10,
ith multiple myeloma, initially underwent autolo-
ous followed by allogeneic HSCT. Only 1 (14%) of
donors of allogeneic HSCT, the sibling for patient
1, was HBsAg positive. The remaining 6 donors (5
iblings and 1 unrelated donor) were HBsAg negative
nd anti–hepatitis B core IgG/anti–HBeAg positive.
welve (75%) of 16 recipients started to receive lami-
udine therapy as primary prophylaxis of HBV reac-
ivation hepatitis, and the other 4 (25%) received it
s rescue (n  2) or secondary prophylaxis (n  2).
herapy commenced at a median of 11 weeks (range,
-62 weeks) before transplantation and extended into
he posttransplantation period to prevent HBV reac-
ivation.
fficacy of Lamivudine Therapy
At the end of follow-up, the median duration of
amivudine therapy for 16 HSCT recipients was 73
eeks (range, 19-153 weeks), including 1 patient who
ontinued therapy (Table 1). In the case of patient 10,
ith multiple myeloma, therapy was once discontin-
ed according to the schedule at 62 weeks because of
emporary disease remission after the initial autolo-
ous HSCT, but it was later re-started when the
isease relapsed, and salvage chemotherapy and allo-
eneic HSCT were given (Table 1).
nitial Response
After lamivudine therapy, 2 (100%) of 2 recipients
patients 7 and 12; Table 1) who took lamivudine as
he rescue medication for HBV reactivation hepatitis
uring chemotherapy achieved a rapid biochemical
esponse. Other recipients had consistently normal (
B&MTiver function tests. In terms of the initial virologic
esponse in all 16 recipients, there was a median max-
mal reduction of 2.54 log10 in the serum HBV DNA
evel (range, 0.28 to 6.72), including undetectable
evels in 3 (19%) of 16 cases (Table 1). An insigniﬁcant
ncrease (ie, variations less than 3-fold) was observed
n 2 recipients (patients 1 and 4), who both had a
ow-titer baseline level (104 copies per milliliter).
oss of HBsAg was seen in 1 (20%) of 5 recipients
patient 7) after 18 weeks of therapy, and temporary
oss of HBsAg was seen in another patient (patient 11;
%) after 32 weeks of therapy.
aintained or End-of-Treatment Response and
reakthrough during Extended Therapy
Fourteen (88%) of 16 recipients achieved an end-
f-treatment or maintained response at the time of
iscontinuation or at the last follow-up, respectively
Table 2). Two (12%) of 16 recipients (patients 1 and
5) were found to have HBV DNA breakthroughs
fter 57 and 27 weeks of therapy, respectively. In the
ase of patient 1 (Figure 1), the breakthrough was
ttributed to possible YMDD mutations and was ac-
ompanied by only a mild increase of serum ALT (60
U/L; see “Chronological Detection of YMDD Mu-
ations”). In the case of patient 15, the breakthrough
as preceded by an episode of acute GVHD grade III
11 weeks after transplantation) and was possibly re-
ated to use of immunosuppressive agents rather than
o mutations.
hronological Detection of YMDD Mutations
Detection of YMDD mutations was initially per-
ormed only on serum samples taken at the time ther-
py was discontinued or at the end of the study period;
chronological analysis during lamivudine therapy
as planned for recipients with detected mutations.
owever, mutations were found in the sera of several
ecipients before therapy, and, therefore, chronologi-
al analysis was performed for all recipients. A YMDD
utation, YVDD, was detected in the sera of 3 (19%)
f 16 recipients before the initiation of therapy (Table 2).
hese data were further supported by the ﬁnding that,
f 18 HBsAg-positive patients who did not receive
amivudine therapy before 1999, sera from 3 (17%)
atients was shown to carry the variants, including 2
25%) of 8 HSCT recipients after transplantation and
(10%) of 10 with different hematologic malignan-
ies. During lamivudine therapy, 10 (63%) of 16 cases
ad mutations detected at variable time points: YVDD
n 9 and YIDD in 1 (Table 2). For the 7 patients with
o preexisting mutations before therapy, mutations
ere ﬁrst detected at a median of 28 weeks of therapy
range, 4-113 weeks). Most of these detected muta-
ions were present within the wild-type viral popula-
ion, as shown in the gel electrophoresis of patient 1
Figure 1).
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Table 1. Characteristics of 16 HBsAg-Positive HSCT Recipients Treated with Lamivudine
Patient No.
Age (y)/
Sex Diagnosis
HBV
Reactivations
before* or at
the Time† of
Lamivudine
Therapy
Virologic Parameters Clinical Course with Lamivudine Therapy
Duration of
Lamivudine
Therapy
(wk)Genotype HBeAg
Variants of
BCP/Precore
Serum HBV DNA
(105 Copies/mL) Chemotherapy‡ HSCT§ GVHD Relapse
Autologous
1 40/M AML No C  / 0.031 No Yes No No 74
2 26/M AML Yes* B  / 3380.000 No Yes No Yes 31
3 23/M AML No B  / 4.576 Yes Yes No No 90
4 45/F NHL Yes—icteric* B  / 0.037 Yes Yes No No 79
5 56/F NHL No C  / 5426.000 Yes Yes No No 105
6 28/M NHL No B  / 1568.000 No Yes No No 36
7 25/M NHL Yes—icteric† C  / 2509.000 Yes Yes No No 19
8 50/M NHL No B  / 9988.000 Yes Yes No No 31
9 19/F HD No B  / 0.996 Yes Yes No No 153
10 45/M MM No B  / 1.671 Yes Yes Yes Yes 97
Allogeneic
11 42/M AML No B  / 0.025 Yes Yes Yes No 102
12 48/M CML-BC Yes† B  / 5197.000 No Yes Yes Yes 120
13 35/M CML-CP No B  / 22.330 No Yes Yes No 122¶
14 51/F CML-CP No B  / 5.818 No Yes Yes No 23
15 45/M CML-CP No B  / 0.026 No Yes Yes No 112
16 35/M NHL No B  / 67.700 Yes Yes No Yes 57
Median 41 (19-56) Yes (4) B/C  13/3 /  5/11 BCP (3), precore (7),
both (4)
14.072 (0.025-9988) Yes (9) Yes (16) Yes (6) Yes (4) 73 (19-153)
(range) M/F  12/4
AML indicates acute myeloid leukemia; NHL, non-Hodgkin lymphoma; HD, Hodgkin disease; MM, multiple myeloma; CML, chronic myeloid leukemia; BC, blast crisis; CP, chronic phase; BCP, basal
core promoter; /, present/absent.
‡Lamivudine therapy given since pretransplantation chemotherapy.
§given just before HSCT.
given during the period of acute and/or chronic GVHD.
¶continued at the last follow-up in February 2005.
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Table 2. Treatment Response of Lamivudine Therapy in 16 HBsAg-Positive HSCT Recipients
Patient No.
Initial* (n  16) Maintained/End of Treatment* (n  16) Sustained* (n  11)†
Survival (mo)
Maximal HBV DNA
Change ( Log10) Biochemical‡
Virological/
Biochemical Breakthrough
YMDD Mutations Virologic/
Biochemical RecurrenceBaseline During
Autologous
1 0.26 NA No Yes   Yes No 43.7§
2 2.70 NA Yes No   NA† NA† 6.8
3 1.73 NA Yes No   Yes No 44.3§
4 0.28 NA Yes No   No Yes 54.1§
5 2.45 NA Yes No   No Yes 48.1§
6 5.59 NA Yes No   Yes No 39.0§
7 4.55 Yes Yes No   Yes No 59.7§
8 3.39 NA Yes No   NA† NA† 2.2¶
9 1.12 NA Yes No   No Yes 36.6§
10 2.62 NA Yes No   NA† NA† 36.9
Allogeneic
11 1.40# NA Yes No   Yes No 30.0§
12 6.72# Yes Yes No   Yes No 39.3§
13 4.35# NA Yes No   NA† NA† 28.0§
14 1.43 NA Yes No   Yes No 39.8§
15 0.72 NA No Yes   Yes No 36.5§
16 3.30 NA Yes No   NA† NA† 5.8
No. of patients
evaluated (%)
Median, 2.54 (range,
6.72 to 0.28)
2/2 (100) 14/16 (88) 2/16 (12) 3/16 (19) 10/16 (63) 8/11 (73) 3/11 (27) Alive/dead  12/4
NA indicates not evaluable; /, present/absent.
*Deﬁnitions as described in “Patients and Methods.”
†Excluding 5 patients who continued lamivudine therapy at their last follow-up.
‡Evaluation only for the 2 recipients with hepatitis due to HBV reactivation at the time of lamivudine therapy.
§Alive at last follow-up.
Died of relapse.
¶Died of sepsis.
#Once achieved an undetectable serum level (ie, 102 copies per milliliter).
E
xtended
L
am
ivudine
T
herapy
in
H
SC
T
R
ecipients
89
B
B
&
M
T
S
D
t
s
d
r
o
(
h
w
r
o
t
1
L
H
2
7
p
o
c
a
o
W
G
d
(
7
r
t
1
(
h
g
t
h
f
s
0
c
a
t
i
b
s
p
D
a
F
m
t
t
1
a
a
S L); ●, v
L. -T. Hsiao et al.
9ustained Response and Recurrence after
iscontinuation of Therapy
Eleven recipients who discontinued lamivudine
herapy were available for evaluation of sustained re-
ponse. With a median follow-up of 30 months after
iscontinuation (range, 6-58 months), 8 (73%) of 11
ecipients had sustained responses; however, 3 (27%)
f 11 had viral recurrences (Table 2). Two patients
patients 5 and 9) only had HBV DNA recurrences;
owever, patient 4 developed icteric hepatitis 31
eeks after discontinuation, which resolved after
einitiation of lamivudine therapy (Figure 2). The
ccurrence of mutations during therapy did not alter
he risk of viral recurrence after discontinuation (P 
.00 by Fisher exact test).
amivudine Therapy and HBV Reactivation
epatitis after Transplantation
With a median follow-up of 39 months (range,
-216 months) after transplantation, 38 (54%) of the
1 HBsAg-positive recipients were found to have
osttransplantation hepatitis, among whom 8 (21%)
f 38 had undergone liver biopsy to determine the
ause. Twenty-nine (79%) of 38 cases were classiﬁed
s acute/transient in terms of duration, and 23 (61%)
f 38 were classiﬁed as icteric in terms of severity.
ith the exception of the cases attributed to acute
igure 1. YMDD mutation–associated breakthrough during exten
yeloid leukemia (patient 1 in Tables 1 and 2), who received
ransplantation, had an HBV DNA (●) breakthrough and an ALT
herapy). With an ampliﬁcation-restriction detection method [29], P
11 and 86 base pairs (bp), respectively. In the lane below, of gel e
nd mutant-type viral population before lamivudine therapy (14 wee
fter transplantation). After discontinuation of therapy, the mutant t
haded block, period of lamivudine therapy; Œ, value of ALT (IU/VHD (n  4), chronic GVHD (n  6), underlying s
0iseases (n  2), and undetermined causes (n  2), 24
24/38, 63% of all posttransplantation hepatitis; 24/
1, 32% of all recipients) cases were identiﬁed as HBV
eactivation hepatitis (Table 3).
HBV reactivation hepatitis had a median onset
ime of 4.5 months after transplantation (range, 0.5-
3.5 months). Twenty (83%) of 35 presented as acute
transient) hepatitis and 16 (67%) of 24 as icteric
epatitis, including 7 cases of fulminant hepatitis. Re-
arding HBV reactivation hepatitis after transplanta-
ion, the univariate and multivariate Cox proportion
azards regression analysis with several independent
actors showed that lamivudine therapy was the only
tatistically signiﬁcant factor, with a hazard ratio of
.122 (with versus without lamivudine therapy; 95%
onﬁdence interval, 0.016-0.908; P  .040; Table 3
nd Figure 3). There was no death due to HBV reac-
ivation hepatitis for recipients of lamivudine therapy,
n contrast to 6 deaths for those without it (P  .174
y log-rank test). There was no difference in overall
urvival between those with and without lamivudine
rophylaxis (P  .530 by log-rank test).
ISCUSSION
Our study used virologic assays, including vari-
nts, mutations, and quantitative HBV DNA, to re-
mivudine therapy. A 40-year-old HBsAg-positive man with acute
ine between 1 week before transplantation and 73 weeks after
crease 56 weeks after transplantation (ie, 57 weeks of lamivudine
ducts of wild-type (YMDD) and mutant-type (YVDD) viruses were
oresis, the mutation in fact preexisted in the mixture of wild-type
re transplantation) and became dominant during therapy (72 weeks
s soon taken over by the wild type (85 weeks after transplantation).
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Extended Lamivudine Therapy in HSCT Recipients
Bor HSCT recipients. Lamivudine therapy effectively
uppresses viral replication through different clinical
ourses for HSCT recipients during the peritrans-
lantation period, as shown by changes in serum
BV-DNA levels. The treatment response is not in-
erior to that for chronic hepatitis B [33,34]. Data
rom our study show that responses are maintained,
ven in recipients who harbor HBV variants of pre-
ore and/or basal core promoter sites. The ﬁndings
re signiﬁcant because patients who harbor these
ariant viruses are at a higher risk of severe or
ulminant hepatitis compared with patients with
ild-type viruses [22,35-37]. These variants account
or 7% to 30% of HBV carriers worldwide, with an
ncreasing prevalence in these hyperendemic areas
38-40].
The chronological detection of YMDD mutations
n our study further clariﬁes prevailing concerns re-
arding the emergence of mutations and associated
reakthrough during extended lamivudine therapy.
ith the high sensitivity of detection assay used in our
tudy [29], a higher proportion (63%) of our patients
ere shown to have these mutations, mainly presenting
s a mixture of wild- and mutant-type viral population,
uring extended lamivudine therapy. Furthermore, pre-
xisting mutations were even shown in lamivudine-un-
reated sera from 6 (18%) of 34HBsAg-positive patients,
s seen in recent articles [41-44]. These ﬁndings sup-
igure 2. Late viral recurrence with icteric hepatitis manifested
BsAg-positive woman with non-Hodgkin lymphoma (patient 4 in
uring pretransplantation chemotherapy (arrow), had received lam
ubsequent chemotherapy and autologous HSCT. Therapy was dis
cteric hepatitis occurred 31 weeks later, with a surge of serum HB
epatitis was resolved after reinitiation of lamivudine therapy. Œ, vort the concept derived from clonal analysis of HBV t
B&MTuasispecies that most of the nucleotide and amino
cid changes during lamivudine therapy were related
o a shift of the dominant HBV strain within preexist-
ng quasispecies [45]. Fortunately, with relatively shorter
reatment durations, the mutation-associated break-
hrough was low in our HSCT recipients, similar to that
n patients who did not receive HSCT [46]. However,
ndings from our study and a previously reported case
nvolving a biochemical breakthrough due to mutations
fter 9 months of lamivudine therapy [17] and the
mergence of YMDD mutations during extended
amivudine therapy for HSCT recipients present a
hallenge that cannot be overlooked.
In agreement with 3 previous reports [16,17,47],
high rate of HBV DNA recurrence (even with
epatitis; 27%) after discontinuation of lamivudine
herapy was found in our study. It is important to
ote that our study illustrated 1 case (patient 10)
ith late recurrence, 31 weeks after discontinua-
ion. In fact, with further application of lamivudine
herapy for HSCT recipients, a close follow-up for
iral recurrence after discontinuation of therapy
ill become important.
Although somewhat limited by the relatively
mall number of patients, this single-institution
tudy in an HBV-hyperendemic area provides direct
vidence in support of prophylactic lamivudine
herapy in HBsAg-positive HSCT recipients. Fur-
eeks after discontinuation of lamivudine therapy. A 45-year-old
1 and 2), who had a previous episode of HBV reactivation hepatitis
e since 20 weeks before transplantation to allow completion of
ued 26 weeks after transplantation; however, viral recurrence with
A levels and the appearance of serum HBeAg and anti-HBc IgM.
ALT (IU/L); ●, value of log10 HBV DNA (copies per milliliter).31 w
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92amivudine as primary prophylaxis, our study fur-
her supports lamivudine therapy as primary pro-
hylaxis in terms of its relative safety and efﬁcacy.
amivudine therapy can commence early in patients
ith evidence of accelerated HBV replication be-
ore the development of overt hepatitis; however,
he capacity for early detection is usually limited by
he cost and frequency of examinations during fol-
ow-up. In addition, lamivudine has been reported
o fail as rescue medication for HBV reactivations in
everal cases after chemotherapy and in HSCT re-
ipients [2,3,48-51]. Because ethical reasons will
urther limit cohort clinical studies designed to in-
estigate this issue, cumulative evidence, including
ata from this study, supports lamivudine use as
rimary prophylaxis in the HSCT setting [17]. In
ddition to the beneﬁts of 1 year of lamivudine
herapy for allogeneic HSCT recipients demon-
trated in the study by Lau et al. [17], our study
urther supports extended lamivudine therapy in
SCT recipients for 1 year, especially for patients
ho commence therapy before transplantation and
or those with complicated posttransplantation dis-
tive HSCT Recipients
HBV Reactivation Hepatitis after Transplantation (n  22)
) Hazard Ratio* 95% CI* P Value*
6) 0.571 0.247-1.322 .191
4) 1
0.969 0.933-1.007 .101
2) 0.996 0.406-2.443 .992
8) 1
1) 0.958 0.409-2.243 .921
9) 1
4) 1.232 0.364-4.165 .737
6) 1
7) 2.545 0.936-6.917 .067
3) 1
9) 2.074 0.884-4.867 .094
1) 1
5) 1.154 0.425-3.135 .778
5) 1
) 0.122¶ 0.016-0.908¶ .040¶
6) 1
2).
 9), chronic myeloid leukemia (n  15), severe aplastic anemia
obinuria (n  1).
ts.
of all factors in this table.igure 3. Curve of cumulative hazards for HBV reactivation hep-
titis after transplantation in HBsAg-positive HSCT recipients ac-
ording to lamivudine therapy. Cox proportion hazards regression
nalysis adjusted by several independent factors showed that lami-
udine therapy was the only statistically signiﬁcant factor, with
azard ratio of 0.122 (with versus without lamivudine therapy; 95%able 3. HBV Reactivation Hepatitis after Transplantation in 71 HBsAg-Posi
Parameters
Recipients (n  71),
No. (%) n (%
ex
Male 44 (62) 10 (4
Female 27 (38) 12 (5
edian age, y (range) 33 (9-60) —
iagnosis
Lymphoma 23 (32)† 7 (3
Nonlymphoma 48 (68)‡ 15 (6
BeAg
Positive 29 (41) 9 (4
Negative 42 (59) 13 (5
LT before transplantation§
Abnormal 9 (13) 3 (1
Normal 62 (87) 19 (8
ource of graft
Allogeneic 43 (61) 17 (7
Autologous 28 (39) 5 (2
se of TBI
Yes 32 (45) 13 (5
No 39 (55) 9 (4
llogeneic donor’s HBsAg¶
Positive 16 (37) 6 (3
Negative 27 (63) 11 (6
amivudine therapy
With 16 (23) 1 (4
Without 55 (77) 21 (9
I indicates conﬁdence interval; TBI, total body irradiation.
By a simple Cox proportion regression analysis of each factor.
Including non-Hodgkin lymphoma (n  21) and Hodgkin disease (n 
Including acute myeloid leukemia (n  16), acute lymphoid leukemia (n
(n  5), multiple myeloma (n  2), and paroxysmal nocturnal hemogl
Within 2 weeks before transplantation for 43 allogeneic HSCT recipienases. It is apparent that the beneﬁt of being free
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Extended Lamivudine Therapy in HSCT Recipients
Brom HBV reactivation seems to exceed the assault
rom lamivudine-associated HBV mutations.
In conclusion, extended lamivudine therapy for
SCT recipients during the peritransplantation period
s effective in suppressing viral replications, thereby sig-
iﬁcantly decreasing posttransplantation hepatitis due to
BV reactivation in HBsAg-positive HSCT recipients.
t is important for these recipients to receive close fol-
ow-up for breakthroughs during extended therapy and
or recurrences after discontinuation.
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